No Data
No Data
Lifecome Biochemistry (002868.SZ) plans to raise no more than 80 million yuan through a simple program placement.
Lifecome Biochemistry (002868.SZ) announced the plan to issue stocks to specific targets in 2024 through a simplified procedure...
Lifecome Biochemistry: Announcement of Revised Performance Forecast for the First Half of 2024
Lifecome Biochemistry (002868.SZ): Shareholder Xiaohan intends to reduce her shareholding by no more than 1.73%.
Lifecome Biochemistry (002868.SZ) announced that Ms. Xiaohan holds 10,453,391 shares of the company's stock (6.73% of the total share capital) and intends to reduce the company's shares by no more than 2,682,600 shares (1.73% of the total share capital) through block trades within three months after 15 trading days from the date of the announcement of the reduction plan.
Lifecome Biochemistry: 2024 Interim Performance Forecast
Lifecome Biochemistry (002868.SZ): Expected to lose 50 to 65 million yuan in the first half of the year.
Lifecome Biochemistry (002868.SZ) announced the performance forecast for the first half of 2024. According to preliminary calculations by the finance department, it is expected to incur a net loss of 50-65 million yuan attributable to shareholders of the listed company in the first half of 2024, compared with a loss of 46.6652 million yuan in the same period last year. Deducting non-recurring gains and losses, the net loss is expected to be 85-98 million yuan, compared with a loss of 65.8977 million yuan in the same period last year. Basic loss per share is expected to be 0.32-0.42 yuan/share; operating revenue is expected to be 0.36-0.38 billion yuan, compared with 0.23 billion yuan in the same period last year.
Lifecome Biochemistry (002868.SZ): signed a supply agreement for methylene salicylic acid peptide with Solvay Biopharmaceuticals Belgium.
Lifecome Biochemistry (002868.SZ) announced on June 28 that it has signed a supply agreement for methylene salicylic acid peptide with Zoetis Belgium S.A. (referred to as “Zoetis”) for the years 2024 to 2026. The agreement covers the supply of methylene salicylic acid peptide for three years.
No Data